12 years after we launched ORATOR, what did we learn?
Three summary slides 👇👇👇

Such an honor to present a multicenter research on neoadj LARC +/- RT boost at #ESTRO24 in Glasgow! 🎉

The II Summer School of Clinical Adaptive is upcoming! Have you already booked you place?

Go visit summerschoolnegrar.com for the application and see you in Negrar next 26-28 June! #radoncs Charles A. Plikerd ESTRO endorsed course

Focal boost for #prostatecancer
IJROBP - The Red Journal home of all of the amazing things you can do with radiation
redjournal.org/article/S0360-…

The II Summer School of Clinical Adaptive Radiotherapy, endorsed by ESTRO, offers a practical approach with real clinical cases, contouring and planning sessions, and live treatments on the machines.
👉 bit.ly/3OT80Cj
#adaptivesummerschool

👀 #havealook at the #AIRO 2024 Timetable!

#theNextGeneration
#AIRO #SIRM #AIMN
#AIRB #AIRO giovani

airoservizi.it/programma-time…

Considering focal treatment for primary prostate cancer? It's a promising option, but uncertainties can be a hurdle. 👉Check our latest publication on focal Brachytherapy for a deeper understanding

sciencedirect.com/science/articl…

Luca Nicosia MD Filippo Alongi Elena Riggenbach Constantinos Zamboglou

An expert consensus on the minimum treatment parameter for HCC.
practicalradonc.org/article/S1879-…

ONE-SHOT 💥 results published!

45 PC patients treated with SBRT 19 Gy/1 fx
- acute GU tox: G1 42.5%. G2 20%
- acute GI tox: G1 12%
- late GI tox: G3 2% (1 pt)
- 2-year mean PSA 0.7 ng/ml

Now waiting for long-term results. Congrats to Thomas Zilli

sciencedirect.com/science/articl….

❔ For #ASCODailyNews , Hidehito HORINOUCHI explores stage III #NSCLC perioperative ICI trials & PACIFIC to answer: What treatment to recommend for a pt w/ potentially resectable disease? Neoadjuvant chemoimmunotherapy or concurrent CRT followed by durvalumab? brnw.ch/21wGZbz

TROG 15.03 FASTRACK II
26Gy/1fx (<4 cm) or 42Gy/3fx (4-10cm) for primary #kidney cancer:
1y LC: 100%
7 cases of G3 toxicity
🎯 #sbrt #radiotherapy #radonc
Waiting for RCT of SABR vs surgery
sciencedirect.com/science/articl…

Interesting and provocative editorial by Timmermann. Can we raise the bar of SBRT efficacy?

sciencedirect.com/science/articl…

Some radoncs have not learned sometimes the worst toxicity is the tumor. There should be nuance in how constraints are applied case to case, when to violate/sacrificewhen to respect.

We need a new paradigm in precision RT. You can't make a Jedi with stormtrooper energy

Treat with RX bone Mets not only in case of symptoms.

-RT delivered prophylactically to asymptomatic,high-risk bone metastases reduced SRE and hospitalizations.

⬆️ in OS with prophylactic RT was also found.

Another important message to change practice
ascopubs.org/doi/abs/10.120…

ilpost.it/2024/02/17/med…

NSABP B-51/RTOG 1304 presented at #NRG2024

💥cN1 breast cancer pts who converted to ypN0 with neoadj chemo
💥no SS DFS or OS benefit to WBRT + RNI or CW RT inc RNI (superiority design)
💥thread below includes details from presentation

1/7

NRG Oncology

How to write a discussion section for a medical research manuscript

Dear friends and colleagues I have the pleasure to invite you to the II Summer School of Clinical Adaptive Radiotherapy next 26-28 June in Negrar, Italy endorsed by ESTRO!
Subscription at:
summerschoolnegrar.com
More infos at:
estro.org/Courses/2024/%…